Establishment of a pediatric COVID-19 biorepository: unique considerations and opportunities for studying the impact of the COVID-19 pandemic on children
Establishment of a pediatric COVID-19 biorepository: unique considerations and opportunities for studying the impact of the COVID-19 pandemic on children
复制标题
DOI：
10.1186/s12874-020-01110-y
复制
发表时间：
2020-09-11
影响因子：
4
通讯作者：
Yonker, Lael M.
中科院分区：
文献类型：
--
作者：
Lima, Rosiane;Gootkind, Elizabeth F.;Yonker, Lael M.
背景COVID-19是由高度传染性和可传播的冠状病毒SARS-CoV-2引起的疾病，已迅速成为一种病态的全球大流行病。尽管SARS-CoV-2感染对儿童的影响在临床上不太明显，但在COVID-19大流行期间以标准化方式从婴儿、儿童和青少年中收集高质量的生物标本对于在儿科人群中建立对该疾病的生物学理解至关重要。这个生物储存库使全球儿科中心能够统一收集样本，通过解决特定的儿科和新生儿COVID-19相关问题来推动我们对COVID-19的理解。方法实施COVID-19生物标本采集研究，包括在紧急护理诊所和医院就诊的患者，SARS-CoV-2感染母亲所生的新生儿和无症状儿童。本文所述的方法详细说明了在临床和研究团队之间建立合作的重要性，以协调患者招募和样本采集、处理和储存的方案。其亦详述于COVID-19疫情激增期间生物库所需的修改。结果新生儿和儿科队列登记面临的考虑因素和挑战进行了描述。为成功采集、处理、储存和数据库管理多种儿科样本（如血液、鼻咽和口咽拭子、痰液、唾液、气管吸出物、粪便和尿液）制定了路线图。使用这种方法，我们招募了327名参与者，他们共提供了972份生物标本。结论：儿童生物标本将是回答有关儿童病毒传播、儿童和成人病毒易感性和免疫反应差异、母亲SARS-CoV-2感染对胎儿发育的影响以及儿童多系统炎症综合征驱动因素等问题的关键。这个生物库中的标本将允许儿童和成人之间进行必要的比较研究，帮助确定当前儿科病毒检测技术的准确性，此外，还可以了解新生儿对SARS-CoV-2感染和疾病异常的暴露。成功建立儿科生物储存库对于深入了解疾病发病机制以及随后制定未来的治疗和疫苗接种策略至关重要。
Background COVID-19, the disease caused by the highly infectious and transmissible coronavirus SARS-CoV-2, has quickly become a morbid global pandemic. Although the impact of SARS-CoV-2 infection in children is less clinically apparent, collecting high-quality biospecimens from infants, children, and adolescents in a standardized manner during the COVID-19 pandemic is essential to establish a biologic understanding of the disease in the pediatric population. This biorepository enables pediatric centers world-wide to collect samples uniformly to drive forward our understanding of COVID-19 by addressing specific pediatric and neonatal COVID-19-related questions. Methods A COVID-19 biospecimen collection study was implemented with strategic enrollment guidelines to include patients seen in urgent care clinics and hospital settings, neonates born to SARS-CoV-2 infected mothers, and asymptomatic children. The methodology described here, details the importance of establishing collaborations between the clinical and research teams to harmonize protocols for patient recruitment and sample collection, processing and storage. It also details modifications required for biobanking during a surge of the COVID-19 pandemic. Results Considerations and challenges facing enrollment of neonatal and pediatric cohorts are described. A roadmap is laid out for successful collection, processing, storage and database management of multiple pediatric samples such as blood, nasopharyngeal and oropharyngeal swabs, sputum, saliva, tracheal aspirates, stool, and urine. Using this methodology, we enrolled 327 participants, who provided a total of 972 biospecimens. Conclusions Pediatric biospecimens will be key in answering questions relating to viral transmission by children, differences between pediatric and adult viral susceptibility and immune responses, the impact of maternal SARS-CoV-2 infection on fetal development, and factors driving the Multisystem Inflammatory Syndrome in Children. The specimens in this biorepository will allow necessary comparative studies between children and adults, help determine the accuracy of current pediatric viral testing techniques, in addition to, understanding neonatal exposure to SARS-CoV-2 infection and disease abnormalities. The successful establishment of a pediatric biorepository is critical to provide insight into disease pathogenesis, and subsequently, develop future treatment and vaccination strategies.